Announces that along with its wholly owned subsidiary, Marvel Biotechnology Inc., it has completed the dosing portion of the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging dog and rat studies for its lead drug candidate MB-204. MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease, and Alzheimer's disease and improved concentration. Marvel Biosciences Corp shares V.MRVL are trading unchanged at $0.10.